Top Markets
#1 EXOD EXOD +56.80%
#2 Arowana Arowana +8.49%
#3 Fake World Assets Fake World Assets +8.26%
#4 Perle Perle +3.98%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +3.72%
#6 Dual Dual +3.58%
#7 Casper Network Casper Network +3.58%
#8 Figure Heloc Figure Heloc +3.49%
#9 Movement Movement +3.23%
#10 Orochi Network Orochi Network +3.13%
Coin of the day
EXOD EXOD
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Evgen Pharma plc Evgen Pharma plc

Evgen Pharma plc

EVG
Clasificación en acciones #38016
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates... Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Precio por acción
$0.00953895
Última sincronización: 2024-05-22
Capitalización bursátil
$1.28M
Cambio (1 día)
0.06%
Cambio (1 año)
0.00%
País
GB
Comercio Evgen Pharma plc (EVG)

Categoría

Healthcare
Ingresos de Evgen Pharma plc (EVG)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Evgen Pharma plc, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Evgen Pharma plc desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE